Benitec, Inc. (BLT.AX) Selects University of California, San Diego (UCSD) as a Site for Phase I/II Clinical Trial of TT-034 in Patients with Hepatitis C Infections
4/16/2013 9:34:46 AM
More...
|
Appointment of Mr Kevin Buchi to Benitec, Inc. (BLT.AX) Board
4/11/2013 11:58:48 AM
More...
|
Benitec, Inc. (BLT.AX) Selects the Duke Clinical Research Unit as a Site for Hepatitis C Phase I/II Clinical Trial
3/22/2013 9:27:29 AM
More...
|
Benitec, Inc. (BLT.AX) Announces Acquisition of Tacere Therapeutics, Inc. and Phase I/II Ready Hepatitis C (HCV) Program
10/11/2012 9:00:27 AM
More...
|
Benitec, Inc. (BLT.AX) Raises AU$8 Million ($8.5 Million) to Forge Ahead with its Gene Silencing Therapeutics: Rights Issue Closes Oversubscribed
5/17/2011 7:51:36 AM
More...
|
Research Report on Benitec, Inc. (BLT.AX) Released
3/24/2011 9:51:40 AM
More...
|
Biomics Biotechnologies and Benitec, Inc. (BLT.AX) Advance RNAi Treatment for Hepatitis B
2/22/2011 11:13:36 AM
More...
|
Benitec, Inc. (BLT.AX) Signs Memorandum Of Understanding With Biomics Biotechnologies In China
7/14/2009 8:49:30 AM
More...
|
Benitec, Inc. (BLT.AX) Double-Stranded Patent Granted in Singapore
11/7/2008 2:37:42 PM
More...
|
Nucleonics Inc. Challenges Dismissal of Counterclaims Against Benitec, Inc. (BLT.AX)
8/7/2007 12:37:58 PM
More...
|
|